SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Costantino who wrote (38)9/16/1996 9:48:00 PM
From: I. Luttichuys   of 1762
 
Rick,
I wanted to add/reiterate some things you may already know but that may make waiting for the relapse data more interesting. NHL (as a cancer) is a disorder of cell accumulation. The cancer, of course, results when the rate at which the cells proliferate is greater than the rate at which they die so the cells accumulate. This protien BCL-2 inhibits cell death (studies have shown) so that you will have less cells dying and more or less lose the balance between cell "birth" and death. A tumor results. All previous therapies I had heard of (at least of relatively acceptable toxicity as Brad clarified) had little effect on levels of BCL-2. Theoretically the presence of BCL-2 does not bode well for the patient in that if it continues to suppress cell death, new cell growth is not balanced by cell loss and relapse occurs. Now IDEC's drug reduced BCL-2 to undetectable levels in 17% of trial subjects. THEORETICALLY without BCL-2 present to inhibit cell death, new cell growth will be balanced by cell loss so relapse might not occur. You are correct in that data will have to be gathered to confirm that in practice this loss of detectable BCL-2 means what we hope it does. But all the same its very interesting.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News